Sugi Predict

Sugi Predict / Compounds / SCHEMBL75070

SCHEMBL75070

SCHEMBL75070

COC(=O)C(N)CC(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ KIF11 P52732 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ TSHR P16473 1/20 0.32
▸ ACHE P22303 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ SLC1A1 P43005 1/20 0.31
▸ LTA4H P09960 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.30
▸ PEPD P12955 1/20 0.30
▸ GFPT1 Q06210 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL75069 0.98 HTT (0.34) HTTCA1CA2KIF11SMN1; SMN2
SCHEMBL16346437 0.85 CA1 (0.38) HTTCA1CA2KIF11SMN1; SMN2
SCHEMBL1067587 0.85 CA1 (0.38) HTTCA1CA2KIF11SMN1; SMN2
SCHEMBL1067592 0.85 CA1 (0.38) HTTCA1CA2KIF11SMN1; SMN2
Hydrochloric Acid SCHEMBL28648906 0.83 CA1 (0.37) CA1CA2KIF11SMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL345242 0.83 CA1 (0.37) CA1CA2KIF11SMN1; SMN2TSHR
Bromide SCHEMBL347135 0.83 CA1 (0.37) CA1CA2KIF11SMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL3873349 0.83 CA1 (0.37) CA1CA2KIF11SMN1; SMN2TSHR
SCHEMBL18124775 0.82 CA1 (0.36) CA1CA2KIF11SMN1; SMN2TSHR
SCHEMBL8213669 0.82 CA1 (0.36) CA1CA2KIF11SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372527-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR ASTRAZENECA UK LIMITED (GB) 2023-11-23 — — US disclosed
US-20230372527-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR ASTRAZENECA UK LIMITED (GB) 2023-11-23 — — US disclosed
US-11325906-B2 Chemical compounds ASTRAZENECA AB (SE) 2022-05-10 — — US disclosed
WO-2022074617-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR ASTRAZENECA UK LIMITED (GB) 2022-04-14 — — WO disclosed
US-20210040084-A1 CHEMICAL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2021-02-11 — — US disclosed
WO-2021013735-A1 PARP1 INHIBITORS ASTRAZENECA AB (SE) 2021-01-28 — — WO disclosed
EP-2914596-B1 HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma AG (DE) 2017-06-21 — — EP disclosed
EP-2914596-B1 HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma AG (DE) 2017-06-21 — — EP disclosed
EP-2914596-A1 HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS Bayer Pharma Aktiengesellschaft (DE) 2015-09-09 — — EP disclosed
EP-2914595-A1 CARBOXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS Bayer Pharma Aktiengesellschaft (DE) 2015-09-09 — — EP disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed
EP-2104665-A2 IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES F. Hoffmann-Roche AG (CH) 2009-09-30 — — EP disclosed
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN-LA ROCHE INC. 2008-05-01 — — US disclosed
WO-2008046758-A2 IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 — — WO disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 — — US disclosed
US-6037367-A Substituted-pent-4-ynoic acids SMITHKLINE BEECHAM CORPORATION (US) 2000-03-14 — — US disclosed
EP-0827495-A4 SUBSTITUTED-PENT-4-YNOIC ACIDS SMITHKLINE BEECHAM CORP (US) 1998-11-04 — — EP disclosed
EP-0827495-A1 SUBSTITUTED-PENT-4-YNOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1998-03-11 — — EP disclosed
WO-1997003945-A1 SUBSTITUTED-PENT-4-YNOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1997-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040084-A1 CHEMICAL COMPOUNDS CYP11B2, CYP11B1, CYP4B1 HTT 2970/4885CA1 2457/4885CA2 2060/4885
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HSD11B1, HSD17B1, HSD17B11 HTT 3436/4885CA1 2926/4885CA2 2859/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 HTT 2401/4885CA1 4305/4885CA2 2535/4885
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR HTT 2137/4885CA1 2689/4885CA2 2603/4885
US-20230372527-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR PARP12, PARP11, PARP1 HTT 2430/4885CA1 3781/4885CA2 3735/4885
US-11325906-B2 Chemical compounds CYP11B2, CYP11B1, CYP4B1 HTT 2970/4885CA1 2457/4885CA2 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.